Physician profile
Jonathan S Kurman
NPI 1184913568
$802,587.20
in general payments reported to CMS, 2019-2025
35 companies · $284K in 2025
The $284K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,484 · 2020: $3,691 · 2021: $54K · 2022: $99K · 2023: $155K · 2024: $202K · 2025: $284K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $377K · Honoraria: $127K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Travel and Lodging: $49K · Food and Beverage: $18K · Education: $4,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $377,098.86 |
| Honoraria | $126,888.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,309.36 |
| Travel and Lodging | $49,244.79 |
| Food and Beverage | $17,572.32 |
| Education | $4,833.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $398,240.04 | 2019-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Ambu A/S | $112,003.71 | 2021-2025 | |
| Verona Pharma, INC. | $103,660.39 | 2025 | Ohtuvayre |
| Medtronic, INC. | $48,626.32 | 2021-2025 | Illumisite |
| Ambu INC. | $30,916.07 | 2022-2025 | |
| Pinnacle Biologics, INC | $27,901.85 | 2019-2025 | Photofrin |
| Merit Medical Systems INC | $23,195.74 | 2023-2025 | Elation Balloon Dilator, Aspira, Aero Stent and Delivery System |
| Cook Incorporated | $18,321.25 | 2021-2024 | |
| Boston Scientific Corporation | $10,590.40 | 2019-2023 | |
| Noah Medical Corporation | $7,316.26 | 2023-2025 | Galaxy |
| Intuitive Surgical, INC. | $7,045.17 | 2019-2024 | Da Vinci Surgical System |
| Ethicon INC. | $4,434.20 | 2019-2024 | Monarch Platform |
| Steris Corporation | $1,802.88 | 2024-2025 | |
| US Endoscopy | $1,500.00 | 2025 | |
| Covidien Lp | $1,321.37 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Erbe USA INC | $1,182.70 | 2020-2022 | |
| Verathon INC. | $900.00 | 2023 | Bronchoscope |
| Cook Medical LLC | $625.79 | 2019-2024 | Blue Rhino, Wayne, Arndt |
| Galvanize Therapeutics, INC | $530.27 | 2024-2025 | Aliya System |
| Pentax of America, INC. | $500.00 | 2022 | |
| Becton, Dickinson and Company | $487.50 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $290.61 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $240.84 | 2022 | |
| Auris Health, INC. | $234.76 | 2019 | |
| Olympus America INC. | $226.66 | 2019-2025 | |
| Bard Access Systems, INC. | $146.38 | 2019 | |
| United Therapeutics Corporation | $123.50 | 2019 | |
| Mylan Specialty L.P. | $46.55 | 2019-2020 | |
| 4dmedical USA INC | $45.25 | 2024 | Ct Lvas |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.76 | 2019 | |
| Mauna Kea Technologies, INC. | $32.48 | 2022 | |
| Olympus Corporation of The Americas | $25.76 | 2019 | |
| Body Vision Medical INC. | $24.04 | 2023 | Lungvision |
| Merck Sharp & Dohme LLC | $12.70 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kurman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.